Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma

the Genoa experience.

A. Garaventa, C. Pianca, M. Conte, M. Nigro, B. De Bernardi, F. Claudiani, P. Stimamiglio, L. Bertolazzi, M. Cabria, G. P. Villavecchia

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45% for patients treated before 1985 to 63% for patients treated in the period of 1985-1989 and to 78% for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86% at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69% and PFS was 26% at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50% of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.

Original languageEnglish
Pages (from-to)58-60
Number of pages3
JournalQuarterly Journal of Nuclear Medicine
Volume39
Issue number4 Suppl 1
Publication statusPublished - Dec 1995

Fingerprint

3-Iodobenzylguanidine
Neuroblastoma
Therapeutics
Disease-Free Survival
Induction Chemotherapy
Residual Neoplasm
Therapeutic Uses
Survivors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Garaventa, A., Pianca, C., Conte, M., Nigro, M., De Bernardi, B., Claudiani, F., ... Villavecchia, G. P. (1995). Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience. Quarterly Journal of Nuclear Medicine, 39(4 Suppl 1), 58-60.

Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma : the Genoa experience. / Garaventa, A.; Pianca, C.; Conte, M.; Nigro, M.; De Bernardi, B.; Claudiani, F.; Stimamiglio, P.; Bertolazzi, L.; Cabria, M.; Villavecchia, G. P.

In: Quarterly Journal of Nuclear Medicine, Vol. 39, No. 4 Suppl 1, 12.1995, p. 58-60.

Research output: Contribution to journalArticle

Garaventa, A, Pianca, C, Conte, M, Nigro, M, De Bernardi, B, Claudiani, F, Stimamiglio, P, Bertolazzi, L, Cabria, M & Villavecchia, GP 1995, 'Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.', Quarterly Journal of Nuclear Medicine, vol. 39, no. 4 Suppl 1, pp. 58-60.
Garaventa, A. ; Pianca, C. ; Conte, M. ; Nigro, M. ; De Bernardi, B. ; Claudiani, F. ; Stimamiglio, P. ; Bertolazzi, L. ; Cabria, M. ; Villavecchia, G. P. / Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma : the Genoa experience. In: Quarterly Journal of Nuclear Medicine. 1995 ; Vol. 39, No. 4 Suppl 1. pp. 58-60.
@article{b71f633ca07945ebbc0f13e5811ee9c1,
title = "Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.",
abstract = "The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45{\%} for patients treated before 1985 to 63{\%} for patients treated in the period of 1985-1989 and to 78{\%} for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86{\%} at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69{\%} and PFS was 26{\%} at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50{\%} of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.",
author = "A. Garaventa and C. Pianca and M. Conte and M. Nigro and {De Bernardi}, B. and F. Claudiani and P. Stimamiglio and L. Bertolazzi and M. Cabria and Villavecchia, {G. P.}",
year = "1995",
month = "12",
language = "English",
volume = "39",
pages = "58--60",
journal = "Journal of Nuclear Medicine and Allied Sciences",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "4 Suppl 1",

}

TY - JOUR

T1 - Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma

T2 - the Genoa experience.

AU - Garaventa, A.

AU - Pianca, C.

AU - Conte, M.

AU - Nigro, M.

AU - De Bernardi, B.

AU - Claudiani, F.

AU - Stimamiglio, P.

AU - Bertolazzi, L.

AU - Cabria, M.

AU - Villavecchia, G. P.

PY - 1995/12

Y1 - 1995/12

N2 - The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45% for patients treated before 1985 to 63% for patients treated in the period of 1985-1989 and to 78% for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86% at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69% and PFS was 26% at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50% of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.

AB - The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45% for patients treated before 1985 to 63% for patients treated in the period of 1985-1989 and to 78% for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86% at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69% and PFS was 26% at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50% of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.

UR - http://www.scopus.com/inward/record.url?scp=0029421731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029421731&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 58

EP - 60

JO - Journal of Nuclear Medicine and Allied Sciences

JF - Journal of Nuclear Medicine and Allied Sciences

SN - 1124-3937

IS - 4 Suppl 1

ER -